Steven Cohen's TRVI Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 1 M shares of Trevi Therapeutics, Inc. (TRVI) worth $12.52 M, representing 0.01% of the portfolio. First purchased in 2024-Q4, this short-term holding has been held for 5 quarters.
Based on 13F filings, Steven Cohen has maintained this position in TRVI for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2025, adding 58,071 shares. Largest reduction occurred in Q1 2025, reducing 1.78 M shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Trevi Therapeutics (TRVI) Holding Value Over Time
Track share changes against reported price movement
Quarterly Trevi Therapeutics (TRVI) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +58,071 | Add 6.17% | 1 M | $12.52 |
| Q3 2025 | -786,747 | Reduce 45.51% | 941,929 | $9.15 |
| Q2 2025 | -639,329 | Reduce 27.00% | 1.73 M | $5.47 |
| Q1 2025 | -1.78 M | Reduce 42.94% | 2.37 M | $6.29 |
| Q4 2024 | +4.15 M | New Buy | 4.15 M | $4.12 |
Steven Cohen's Trevi Therapeutics Investment FAQs
Steven Cohen first purchased Trevi Therapeutics, Inc. (TRVI) in Q4 2024, acquiring 4,150,237 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Trevi Therapeutics, Inc. (TRVI) for 5 quarters since Q4 2024.
Steven Cohen's largest addition to Trevi Therapeutics, Inc. (TRVI) was in Q4 2024, adding 4,150,237 shares worth $17.1 M.
According to the latest 13F filing for Q4 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 1,000,000 shares of Trevi Therapeutics, Inc. (TRVI), valued at approximately $12.52 M.
As of the Q4 2025 filing, Trevi Therapeutics, Inc. (TRVI) represents approximately 0.01% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Trevi Therapeutics, Inc. (TRVI) was 4,150,237 shares, as reported at the end of Q4 2024.